Yttrium-90 hepatic radioembolization‑related biliary injury - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Yttrium‑90 Hepatic Radioembolization‑Related Biliary Injury – Patient Guide

Yttrium‑90 Hepatic Radioembolization‑Related Biliary Injury

Overview

Yttrium‑90 (Y‑90) radioembolization, also known as trans‑arterial radioembolization (TARE), is a minimally invasive therapy used to treat primary and secondary liver cancers such as hepatocellular carcinoma (HCC) and colorectal liver metastases. Tiny glass or resin microspheres loaded with the radioactive isotope Y‑90 are delivered through the hepatic artery directly to tumor tissue, where they emit high‑energy beta radiation that destroys cancer cells while sparing most healthy liver parenchyma.

Although TARE is generally well‑tolerated, the biliary system (gallbladder and intra‑hepatic bile ducts) can be injured by radiation, ischemia, or mechanical trauma from the microspheres. This condition is termed **Yttrium‑90 hepatic radioembolization‑related biliary injury**. It encompasses a spectrum that ranges from mild cholangitis and bile duct strictures to severe biliary necrosis and liver abscess formation.

Who it affects: Most patients undergoing TARE are adults with liver‑dominant tumors; the median age is 60–70 years. Biliary injury is reported in 5‑15 % of treated patients, with higher rates in those receiving high microsphere activity, resin microspheres, or pre‑existing biliary disease.[1][2]

Symptoms

Biliary injury may present weeks to months after the procedure. Symptoms can be subtle at first and then progress. Common manifestations include:

  • Abdominal pain – often right‑upper‑quadrant (RUQ) or epigastric, may be dull or colicky.
  • Jaundice – yellowing of the skin and eyes caused by elevated bilirubin.
  • Fever and chills – sign of cholangitis or secondary infection.
  • Pruritus – itching due to bile salt accumulation.
  • Dark urine / pale stools – classic cholestatic pattern.
  • Nausea or vomiting – especially when pain is severe.
  • Fatigue – a nonspecific but common complaint.
  • Unexplained weight loss – may reflect malabsorption.
  • Elevated liver enzymes – especially alkaline phosphatase (ALP) and gamma‑glutamyl transferase (GGT).
  • Septic signs – high‑grade fever, hypotension, altered mental status (indicates possible liver abscess).

Symptoms often overlap with other post‑TARE liver changes, so a thorough evaluation is essential.

Causes and Risk Factors

Mechanisms of injury

  • Radiation‑induced cholangiopathy – beta particles damage the epithelium of bile ducts, leading to inflammation, fibrosis, and stricture formation.
  • Ischemic insult – microspheres can occlude the peribiliary arterial plexus, reducing blood flow to the ducts.
  • Mechanical trauma – large or aggregated microspheres may physically obstruct small ducts.
  • Secondary infection – strictures predispose to bacterial overgrowth and cholangitis.

Patient‑related risk factors

  • Pre‑existing biliary disease (cholestasis, primary sclerosing cholangitis, previous biliary surgery).
  • High total activity (> 150 Gy to liver) or high lung shunt fraction (> 20 %).
  • Use of resin microspheres (higher embolic load) compared with glass microspheres.
  • Large tumor burden (> 50 % of liver volume), especially when lesions are near major bile ducts.
  • Diabetes mellitus or vascular disease that impairs microvascular perfusion.
  • Prior hepatic radiation therapy or systemic chemotherapy that sensitises biliary epithelium.

Diagnosis

Early detection relies on a combination of clinical suspicion, laboratory tests, and imaging.

Laboratory evaluation

  • Serum bilirubin (total and direct) – often elevated.
  • Alkaline phosphatase (ALP) and GGT – markers of cholestasis.
  • Transaminases (AST/ALT) – may be mildly raised.
  • Complete blood count – leukocytosis suggests infection.
  • Blood cultures if fever is present.

Imaging studies

  • Contrast‑enhanced CT scan – identifies ductal dilatation, strictures, and abscesses.
  • Magnetic resonance cholangiopancreatography (MRCP) – non‑invasive gold standard for visualising biliary anatomy and strictures.
  • Endoscopic retrograde cholangiopancreatography (ERCP) – diagnostic and therapeutic; allows direct visualization, brush cytology, and stent placement.
  • Ultrasound with Doppler – useful for detecting fluid collections and assessing hepatic arterial flow.
  • Positron emission tomography (PET‑CT) – helps differentiate tumor progression from radiation‑induced changes.

Diagnostic criteria

A diagnosis of Y‑90‑related biliary injury is generally made when:
  1. Symptoms of cholestasis/cholangitis appear ≥ 2 weeks after TARE,
  2. Laboratory cholestatic pattern is present, and
  3. Imaging demonstrates biliary ductal abnormalities not explained by tumor progression or other causes.

Treatment Options

Management is individualized based on severity, extent of injury, and overall liver function (Child‑Pugh class). The goals are to relieve obstruction, control infection, and preserve liver reserve.

Medical therapy

  • Antibiotics – broad‑spectrum coverage (e.g., piperacillin‑tazobactam) for cholangitis; adjust based on culture results.
  • Ursodeoxycholic acid (UDCA) – may improve bile flow and reduce cholestasis.
  • Analgesics – acetaminophen preferred; avoid NSAIDs in significant liver dysfunction.
  • Pruritus control – cholestyramine, rifampin, or sertraline as per provider guidance.

Endoscopic and percutaneous interventions

  • ERCP with stent placement – first‑line for focal strictures; plastic or fully covered self‑expanding metal stents (FCSEMS) maintain ductal patency.
  • Balloon dilation – can be combined with stenting for tight strictures.
  • Percutaneous transhepatic biliary drainage (PTBD) – alternative when ERCP is technically impossible.
  • Abscess drainage – percutaneous catheter placement under CT/US guidance.

Surgical options

Rarely required, but may include:

  • Roux‑en‑Y hepaticojejunostomy for severe, refractory strictures.
  • Liver segmentectomy when a localized necrotic segment is causing infection.

Supportive measures

  • Optimising nutrition – high‑protein, low‑fat diet; consider medium‑chain triglyceride supplements if fat malabsorption is present.
  • Hydration and electrolyte balance.
  • Regular monitoring of liver function tests (LFTs) every 2‑4 weeks during treatment.

Living with Yttrium‑90 Hepatic Radioembolization‑Related Biliary Injury

Daily management tips

  • Track symptoms – keep a diary of pain, jaundice, fever, and stool changes.
  • Medication adherence – take antibiotics, UDCA, and anti‑pruritic agents exactly as prescribed.
  • Nutrition – small, frequent meals; avoid fried foods and large fatty meals that can exacerbate biliary stasis.
  • Hydration – aim for at least 2 L of water daily unless fluid restriction is advised.
  • Activity – gentle walking promotes bile flow; avoid vigorous exertion that could increase intra‑abdominal pressure.
  • Stent care – if you have a biliary stent, attend scheduled endoscopic or radiologic follow‑ups (usually every 3‑6 months) to assess for occlusion.
  • Vaccinations – stay up‑to‑date on hepatitis A and B vaccines; consider pneumococcal and influenza vaccines to lower infection risk.
  • Psychosocial support – join liver‑cancer survivor groups; counseling can help cope with chronic illness.

Prevention

While the radiation dose cannot be eliminated, several strategies reduce the likelihood of biliary injury:

  • Pre‑procedure planning – detailed mapping of hepatic arterial anatomy with cone‑beam CT; avoid non‑target embolisation of the cystic artery.
  • Microsphere selection – using glass microspheres (lower embolic load) for patients with known biliary disease.
  • Activity dosing – calculate individualized Y‑90 activity based on liver volume and tumor burden; keep total liver dose < 120 Gy when possible.
  • Prophylactic antibiotics – a single peri‑procedural dose is often given to reduce early infection risk.
  • Post‑procedure imaging – early (within 48 h) nuclear medicine scans to confirm distribution and identify unexpected shunting.
  • Liver‑protective agents – although evidence is limited, some centers use UDCA before and after TARE in high‑risk patients.

Complications if Untreated

Unmanaged biliary injury can progress to serious, life‑threatening conditions:

  • Severe cholangitis – can lead to sepsis, multi‑organ failure, and death.
  • Biliary cirrhosis – chronic cholestasis promotes fibrosis and eventual liver failure.
  • Liver abscess – may require prolonged antibiotics and percutaneous drainage.
  • Portal hypertension – secondary to fibrosis, increasing risk of variceal bleeding.
  • Loss of future liver reserve – limiting options for subsequent cancer therapies.

When to Seek Emergency Care

Go to the nearest emergency department or call 911 if you develop:
  • High‑grade fever (≥ 38.5 °C / 101.3 °F) with chills.
  • Severe, sudden RUQ or abdominal pain that does not improve with pain medication.
  • Rapidly worsening jaundice or dark urine accompanied by pale stools.
  • Signs of confusion, dizziness, or low blood pressure (possible sepsis).
  • Vomiting blood or passing black, tarry stools (possible bleeding from a liver lesion or ulcer).
Prompt treatment can prevent organ failure and improve survival.

References

  1. Mayo Clinic. Yttrium‑90 Radioembolization (SIR-Spheres). 2023. https://www.mayoclinic.org
  2. Gaba RC, et al. Biliary complications after Y‑90 radioembolization. J Vasc Interv Radiol. 2021;32(9):1452‑1460.
  3. American College of Radiology. Practice guideline for hepatic radioembolization. 2022.
  4. World Health Organization. Liver cancer. 2022. https://www.who.int
  5. Cleveland Clinic. Biliary Strictures: Diagnosis and Treatment. 2024. https://my.clevelandclinic.org
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References